Soligenix’s Thermostable Filovirus Vaccine Program Has Potential For Global Impact

Company’s ThermoVax® platform has demonstrated protection against potentially lethal Ebola viruses

Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharma company focused on developing and commercializing products to treat rare diseases continues work on its vital vaccine development program as a new outbreak of Sudan ebolavirus is declared in Uganda.

While there is a vaccine for Zaire ebolavirus, there is no vaccine or therapeutic for Sudan ebolavirus. Ebola viral diseases are severe and often fatal illnesses with no approved post-exposure therapies, highlighting the critical need for effective vaccines.

A heat stable vaccine in a single vial format, such as Soligenix’s ThermoVax® candidates, would significantly enhance future public health responses to outbreaks.

What you need to know

  • Soligenix’s vaccine provides 100% protection in non-human primates against Sudan ebolavirus
  • The company’s vaccines have been shown to maintain full potency and thermostability (104 degrees Fahrenheit for 12 weeks) demonstrating the broad applicability of its heat stable vaccine platform;
  • Soligenix’s work has demonstrated the feasibility of rapid and efficient manufacturing, as well as the ability to thermostabilize multiple antigens that can be stored at temperatures exceeding 100 degrees Fahrenheit.

 A pre-IND meeting with the FDA to discuss the clinical development of this vaccine candidate is expected  to be initiated within the next 12 months.

Disclaimer

This communication was produced by Investors Prism, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

About the Author

Soligenix’s Thermostable Filovirus Vaccine Program Has Potential For Global Impact

Editor Investors Prism